Medical societies shunning pharma support

Doctors are fomenting a different sort of rebellion against the interwoven mesh of drug company-doctor relationships. Medical societies long dependent on Pharma funding, such as the American College of Rheumatology, are trying to wean themselves. Prominent med schools are curtailing or downright prohibiting payments to doctors from drug reps. Longtime critics of the practice--such as Dr. Charles Brody of the University of Texas--say there's been a "sea change." Whether it will fully turn the tide remains to be seen.

- read the report from The Los Angeles Times

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.